United States: New Evaluation Of Medicaid Incentive Programs Shows Need For Improvement

Policymakers at both the federal and state levels have, in recent years, supported incentive programs designed to influence Medicaid beneficiary behavior, in the hopes that such behavioral changes will improve beneficiaries' health and save the program money. Section 4108 of the Affordable Care Act (ACA) mandated the creation of an incentive program specifically aimed at individuals with chronic diseases, known as the Medicaid Incentives for Prevention of Chronic Diseases (MIPCD) program. In addition, some states have created Section 1115 demonstrations that include incentives for beneficiaries who comply with certain healthy behaviors. The recently released Medicaid managed care rule provides new authority for states to use incentive programs in the context of Medicaid managed care and even for network providers within Medicaid managed care organization (MMCO) networks.

A recent US Department of Health & Human Services report (HHS Report) to Congress that was based on an independent evaluation of the MIPCD demonstrations by RTI International (RTI Report) casts doubt on the short-term cost-effectiveness of these incentive programs. The HHS Report should be used by the Centers for Medicare & Medicaid Services (CMS) and states to emphasize the need for careful design of incentive programs.

Background

In September 2011 CMS awarded MIPCD demonstration grants to 10 states under the authority of ACA section 4108, which calls for states to "develop evidence-based prevention programs that provide incentives to Medicaid beneficiaries to participate in and complete the MIPCD program."[1] Section 4108 also requires the demonstrations to be evaluated on:

  • The effect of such programs on the use of health care services by Medicaid beneficiaries participating in the program;
  • The extent to which special populations (including adults with disabilities, adults with chronic illnesses and children with special health care needs) are able to participate in the program;
  • The level of satisfaction of Medicaid beneficiaries with respect to the accessibility and quality of health care services provided through the program; and
  • The administrative costs incurred by state agencies that are responsible for administering the program.

CMS awarded five-year grants to the following states:

  • California ($9.9 million)
  • Connecticut ($9.9 million)
  • Hawaii ($9.9 million)
  • Minnesota ($9.9 million)
  • Montana ($0.6 million)
  • Nevada ($3.6 million)
  • New Hampshire ($9.9 million)
  • New York ($10 million)
  • Texas ($9.9 million)
  • Wisconsin ($9.2 million)[2]

The states used this opportunity to design prevention programs around different populations and different chronic conditions. Incentives and interventions were designed to address smoking cessation, diabetes prevention and management, hypertension and weight reduction. The amount of savings an individual could receive varied widely by type of activity, such as attending a class, completing a primary care appointment or filling a prescription. Participants in New Hampshire, for example, could receive up to $1,860 annually for weight loss and $415 for smoking cessation.

Key RTI Report findings

The demonstration results on the required evaluation elements described above are mixed, both individually and collectively. On the positive side, the results show that special populations are able to participate and that the level of satisfaction among beneficiaries is very high: "Across all states, 94 percent of participants were very or somewhat satisfied with the programs, and about 74 percent said they would recommend the program to their friends or families. Similarly, participants found the programs to be very accessible. With regards to the objective of preventing chronic disease, participants thought the programs helped them make healthy changes in their behavior. Not surprisingly, participants liked receiving incentives, but they thought that the impact of the incentives was strongest in encouraging them to enroll in the program and less important later when improving health became a more important motivator."[3]

However, the results concerning the effect on the use of health care services and administrative costs are substantially less promising. CMS had initially set a 15 percent limit on administrative costs, but the evaluators estimate administrative costs to represent about 25 percent of overall expenditures.[4] Administrative costs may decline over time as more people are enrolled and there is greater use of the incentives, but the higher-than-expected costs could be a deterrent to the spread of incentive programs if CMS or states impose hard caps on administrative costs.  

The majority of expenditures were attributed to services. Of particular interest, incentive payments during the first three years represented only about 7 percent of expenditures. This is likely to change over time for several reasons—most states fell far short of their enrollment goals, individuals did not have sufficient time to complete their programs in order to receive incentive payments, and states likely overestimated the amount of incentives that would be paid. States were challenged by delays and changes as programs moved from design to implementation. As one interviewee described, "Everyone underestimates the challenges of logistics and implementation."[5]

The critical question of whether these incentive programs have reduced health care costs has not yet been answered. The demonstrations generally track process measures, but not outcomes. The RTI Report concludes, "[t]o date, the claims analysis ... has found that the incentive programs have statistically insignificant effects on utilization and expenditures. However, the claims data are not complete, and even if the incentives prevent chronic diseases, the effects of prevention on utilization and expenditures may not be apparent in the short term."[6]

RTI acknowledges that claims data will continue to be analyzed and the evaluation continues. A final report to Congress on the demonstrations is expected after the CMS evaluation is completed in April 2017.

Lessons for states and CMS

Even though the evaluation continues, there are lessons to be learned from these demonstrations. The report's findings raise a question as to whether MMCOs have sufficient incentive to invest in incentive programs. While incentive payments may qualify as "quality improvement" activities and thus can be treated favorably in calculating an MMCO's medical loss ratio (MLR), the cost of designing, implementing, and administering the incentive program is not. The demonstrations clearly show that administrative costs are higher than expected and remain so beyond the first year of a program. 

RTI clearly indicates that, if there are health care savings, they are not apparent in the short term. Given the disruptions entailed in enrollment and disenrollment processes, MMCOs may be hesitant to start costly programs that may not produce a reasonable return on investment. CMS and states should consider ways to let an MMCO keep an individual as a member for longer periods of time without disruption, to encourage plans to invest in incentive programs and other efforts to improve health and lower costs over the long term. CMS should also consider changing how prevention and wellness incentives are treated under the MLR provisions of the Medicaid managed care rule. 

Conclusion

Well-designed incentive programs have been successful in the commercial market. Although the recent outside evaluator report provides no clear consensus with respect to success with Medicaid populations, the report does provide some future direction. Dentons experts can assist states, health plans and their partners who specialize in offering incentive programs navigate the regulatory challenges they face. 

Footnotes

[1] US Department of Health and Human Services, Second Report to Congress: Medicaid Incentives for Prevention of Chronic Diseases Evaluation (HHS Report), June 2016 (available at https://innovation.cms.gov/Files/reports/mipcd-secondrtc.pdf), at 2 (emphasis added); RTI International, Independent Assessment Report: Medicaid Incentives for Prevention of Chronic Diseases Evaluation (RTI Report), April 2016 (available at https://innovation.cms.gov/Files/reports/mipcd-secondrtc-indpassessmentrpt.pdf), at 9 (emphasis added).

[2] Disclosure: Dennis Smith was Secretary of the Wisconsin Department of Health Services at the time of award and served in that position until March 2013.

[3] RTI Report at 209.

[4] RTI Report at 209.

[5] RTI Report at 39.

[6] RTI Report at 210.

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
26 Sep 2018, Conference, New York, United States

Dentons is delighted to support a global IT services and consulting firm Miratech as an event host partner at their annual conference called M-Force18 New York on September 27th. The event will be held at Dentons New York office in the heart of Midtown Manhattan, opposite Rockefeller Center.

2 Oct 2018, Seminar, Dallas, United States

We are pleased to offer a program of five sessions designed specifically for in-house counsel. Topics will include:

  • In-house corporate ethical issues
  • What recent Supreme Court decisions mean for business
  • Keeping lawyers out of your benefit plans
  • Litigation tactics for in-house counsel
  • Employment issues in the age of #MeToo
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions